Skip to main content
OpenTrials
Completed

NCT Number: NCT00000271

New Approaches to Cocaine Abuse Medications (A) - 6

The purpose of this study is to measure the effect of desipramine in cocaine abusers selected for major depression or dysthymia.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–60 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Research Foundation for Mental Hygiene

New York, 10032, United States

About this study

This is a randomized, 12-week, double-blind, 'placebo-controlled trial of outpatients meeting DSM-III-R criteria for cocaine dependence and major depression or dysthymia (by SCID interview). Participants were treated with desipramine, up to 300 mg per day, or matching placebo. All patients received weekly individual manual-guided relapse prevention therapy. Weekly outcome measures included the Clinical Global Impression Scale, self-reported cocaine use and craving, urine toxicology, and the Hamilton Depression Scale.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion:

  • Meets DSM-IV criteria for current cocaine dependence.
  • Used cocaine at least one day in the past month.
  • Currently meets DSM-IV criteria for Major Depression or Dysthymia.
  • Depressive disorder is either:
  • primary (antedates earliest lifetime substance abuse or
  • persistent during 6 months of abstinence in the past or
  • at least 3 months duration in the current episode
  • Age 18-60.
  • Able to give informed consent and comply with study procedures.

Exclusion:

  • Meets DSM-IV criteria for past mania (i.e. bipolar disorder), schizophrenia or any psychotic disorder other than transient psychosis due to drug abuse.
  • History of seizures.
  • History of allergic reaction to desipramine or imipramine.
  • Chronic organic mental disorder.
  • Significant current suicidal risk.
  • Pregnancy, lactation or failure in sexually active female patients to use adequate contraceptive methods.
  • Unstable physical disorders which might make participation hazardous such as hypertension, hepatitis or diabetes.
  • Coronary vascular disease as indicated by history or suspected by abnormal ECG or history or cardiac symptoms.
  • Cardiac conduction system disease as indicated by QRS duration >0.11.
  • Current use of other prescribed psychotropic medications within the last 2 weeks.
  • History of failure to respond to a previous adequate trial of desipramine or another tricyclic antidepressant.
  • Currently meets criteria for another substance dependence disorder (DSM-IV) other than nicotine, marijuana or alcohol.

Treatment and study plan

Desipramine

Drug

Participants were treated with desipramine, up to 300 mg per day, or matching placebo. All participants received weekly individual manual-guided relapse prevention therapy.

Other names: desmethylimipramine

Placebo

Drug

Participants were treated with matching placebo. All participants received weekly individual manual-guided relapse prevention therapy.

Primary outcomes

  1. Cocaine Use

    Time frame: Weekly over a 12 week period.

    Clinical Global Impression Scale, self-reported cocaine use and craving, urine toxicology.

  2. Depression

    Time frame: Bi-weekly over a 12 week period.

    Hamilton Depression Scale

Sponsors and collaborators

Lead sponsor

New York State Psychiatric Institute

Other

Collaborators

  • National Institute on Drug Abuse (NIDA)

Registry information

Official study title

New Approaches to Cocaine Abuse Medications (A)

Important dates

Study start
1995
Primary completion
2002
Study completion
2002
First posted
Sep 21, 1999
Registry last updated
Jul 5, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.